Clinical Trial Update: Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating mogamulizumab in combination with DA-EPOCH or CHOEP for aggressive T-cell lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Yale University | Conditions: T Cell Lymphoma, T-cell Lymphoma | Phase 2 | Status: RECRUITING